Drug/Drug Interactions in the Elderly

Bruce G. Pollock, M.D., Ph.D.

- Compared to the rate of ADRs among adults age 20-29, the rate among adults age 80+ is which of the following:
- A. Similar
- B. Twice as great
- C. Greater than 5 x as frequent
- D. Greater than 10 x as frequent

- Commonly prescribed psychiatric medications are substrates of which of the following C450 enzymes?
- A. 1A2
- B. 2D6
- C. 3A4
- D. All of the above

- Which of the following 3A inhibitors can be associated with significant drug/drug interactions when co-administered with a 3A substrate?
- A. Ketoconazole
- B. Erythromycin
- C. Calcium antagonists
- D. Any of the above

- Which of the following medications has anticholinergic properties?
- A. Furosemide
- B. Warfarin
- C. Ranitidine
- D. Digoxin
- E. All the above

- The risk of drug/drug interactions is increased by which of the following?
 - A. Narrow therapeutic index of co-administered agent
 B. Highly potent co-administered enzyme inducer or inhibitor
 - C. Greater sensitivity to adverse effects in elderly patients
 - D. Co-administration of multiple drugs
 - E. All the above


Major Teaching Points

- Elderly patients are highly vulnerable to drug/drug interactions
- Two important types of drug/drug interactions to understand and prevent are:
 - Pharmacokinetic interactions based on drug metabolism through the cytochrome P450 system
 - Pharmacodynamic interactions based on additive serum anticholinergicity

Brief Outline

- Adverse drug interactions' relationship to age, location, number of prescribed drugs
- Cytochrome P450 drug interactions
- Drug interactions based on additive serum anticholinergicity
- Coping with drug/drug interactions
 Suggested readings


Adverse Drug Reactions (ADRs) as a Function of Increasing Age



Adverse Drug Reactions in the Nursing Home

Sychoactive medications (antipsychotics, antidepressants, and sedatives/hypnotics) and anticoagulants were the medications most often associated with preventable ADRs

Relationship Between Prescribing Rate and Prevalence of Potential Drug Interactions




Nolan L, O'Malley K. Age Ageing. 1989;18:52-56.

11

Clinical Dilemma

- Number of possible drug interactions too large to memorize
- Difficult to determine which interactions are important
- Conflicting promotional claims

Cytochrome P-450 Enzyme Subtypes



| CYP isoform | Representative substrates |
|-------------|---|
| 1A2 | Caffeine, theophylline, tacrine |
| 2B6 | Propofol, bupropion |
| 2C9 | Phenytoin, S-warfarin, tolbutamide, NSAIDs |
| 2C19 | Omeprazole (partial contributor to many) |
| 2D6 | Some CNS and cardiac drugs |
| 2E1 | Fluranes, chlorzoxane |
| 3A | (many) |
| | |

<u>CYP3A</u>

- High abundance
- Present in G.I Tract
- No polymorphism, but high individual variability

CYP3A Substrates

| Complete | Partial |
|---|---------------|
| Benzodiazepines (short t _{1/2}) | Zolpidem |
| Buspirone | Amitriptyline |
| Trazodone | Imipramine |
| Nefazodone | Sertraline |
| Cyclosporine | Citalopram |
| Statins | Diazepam |
| Calcium antagonists | Clozapine |
| Quinidine | |
| Protease Inhibitors | |
| Sildenafil | |

CY3A Inhibitors

| High Risk | Moderate Risk |
|---------------------|------------------|
| Ketoconazole | Fluconazole |
| Itraconazole | Fluvoxamine |
| Nefazodone | Fluoxetine |
| Ritonavir (acute) | Grapefruit juice |
| Erythromycin | Other HIV PIs |
| Clarithromycin | Delavirdine |
| Calcium Antagonists | Cimetidine |
| | |


CYP3A Inducers

*****Rifampin

- * Barbiturates
- Carbamazepine
- Ritonavir (chronic)
- * Nevirapine

Hypericum perforatum (St. John's Wort)


CYP3A4: Verapamil




Racemic verapamil clearance data are plotted versus age for women (*solid circles*) and men (*open circles*). The *solid line* represents the regression of clearance versus age relationship in women (P < .004) and the *broken line* represents the regression of clearance versus age in men (regression not significant).

Schwartz JB, et al. Clin Pharmacol Ther. 1994;55:509-517.

St. John's Wort



CYP1A2 Phenotyping (Caffeine) Results Before and After Estrogen Treatment of Healthy Postmenopausal Women



Pollock BG, et al. J Clin Psychopharmacol. 2000;20:137-140.

<u>Cytochrome P-450:</u> Enzymes and Selected Substrates

| 1A2 | 2C | 2D6 | 3A4 |
|-----------------|---------------|-------------|------------------------------|
| Theophylline | Phenytoin | Codeine | Antihistamines |
| Warfarin | Warfarin | Venlafaxine | Calcium channel blockers |
| Antipsychotics | Amitriptyline | Trazodone | Carbamazepine |
| Benzodiazepines | Clomipramine | Risperidone | Cisapride |
| Fluvoxamine | Omeprazole | Haloperidol | Corticosteroids |
| | | Tramadol | Cyclosporine |
| | | β-Blockers | Fentanyl |
| | | | Protease inhibitors |
| | | | Statins |
| | | | Triazolo- benzodiazepines |

Michalets EL. *Pharmacotherapy*. 1998;18:84 -112. Cupp MJ, Tracy TS. *Am Fam Physician*. 1998;57:107-116.

Inhibition of Human Cytochrome P-450 Isoenzymes by Newer Antidepressants

Cytochrome P-450 Isoenzyme

| Antidepressant | 1A2 | 2C9 | 2C19 | 2D6 | 2E1 | 3A |
|------------------------|-----------------------|-----|---------|-----------------|---|-----|
| Fluoxetine | 18 States (* + 16) | ++ | + to ++ | +++ | | の出生 |
| Norfluoxetine | + + + | ++ | + to ++ | +++ | 19 - 1 9 - 19 | ++ |
| Sertraline | 540-660 + 3540 | + | + to ++ | + | | + |
| Desmethylsertraline | 1 | + | + to ++ | + | | + |
| Paroxetine | Sal Street | + | The the | +++ | 75 12 | + |
| Fluvoxamine | +++ | ++ | +++ | 889 + 30 | | ++ |
| Citalopram | La serie de la com | 0 | 0 | 0 | 0 | 0 |
| R-Desmethylcitalopram | 0 | 0 | 0 | + | 0 | 0 |
| Escitalopram | 0 | 0 | 0 | 0 | 0 | 0 |
| S-Desmethylcitalopram | 0 | 0 | 0 | 0 | 0 | 0 |
| Nefazodone | 0 | 0 | 0 | 0 | 24.5. <u></u> 사람() | +++ |
| Triazoledione | 0 | 0 | 0 | 0 | 9 | + |
| Hydroxynefazodone | 0 | 0 | 0 | 0 | 70. 14 | +++ |
| Venlafaxine | 0 | 0 | 0 | 0 | | 0 |
| O-Desmethylvenlafaxine | 0 | 0 | 0 | 0 | 1 - C - C - C - C - C - C - C - C - C - | 0 |
| Mirtazapine | 0 | | 1 | + | 130 <u></u> | 0 |


0 = minimal or zero inhibition.

- + = mild inhibition.
- ++ = moderate inhibition.
- +++ = strong inhibition.

= no data available.

Greenblatt DJ, et al. *J Clin Psychiatry*. 1998;59(suppl 15):19-27. von Moltke LL, et al. *Drug Metab Disposition*. 2001;29:1102-1108.

Incidence of Bleeding During Anticoagulant Therapy



Beyth RJ, Schorr RI. Drugs Aging. 1999;14:231-239.

American Medical Directors Association "Top 10" Drug Interactions Includes:

Warfarin with: N N P S

NSAIDs Macrolides Phenytoin Sulfa Drugs Quinolones

Warfarin Metabolism


Fluoxetine S-warfarin CYP2C9 Fluvoxamine (Sertraline) (Paroxetine) **Fluvoxamine** CYP1A2 **R**-warfarin (major pathway) (Fluoxetine) (Sertraline) (Paroxetine)



R-warfarin CYP2C19 (minor pathway) & CYP3A4

26

Platelet Activation in Depressed Patients With Ischemic Heart Disease After Paroxetine or Nortriptyline Treatment



 Effect of paroxetine () and nortriptyline () on PF4 plasma levels in depressed patients with ischemic heart disease. Data presented are mean ± SEM

**P* < .05 versus baseline levels. PF4 = platelet factor 4. Pollock BG, et al. *J Clin Psychopharmacol.* 2000;20:137-140.

Anticholinergic Medications Commonly Prescribed in the Elderly

Commonly Prescribed in the Elderly

- Furosemide
- * Digoxin
- Theophylline
- Warfarin
- Prednisolone
- Triamterene and hydrochlorothiazide

- Nifedipine
- Isosorbide
- Codeine
- Cimetidine
- Captopril
- * Ranitidine
- Dipyridamole

Age, Sex, Education, Number of Medications, <u>MMSE score, and SA (N = 201)</u>

| Mean (SD) Age | 78.2 (5.2) |
|--|---------------|
| Female (N, %) | 122 (60.7%) |
| Education (< high school) | 38.3 % |
| Number of Medications | 5.2 (3.4) |
| Number of Anticholinergic Medications | 0.91 (1.23) |
| MMSE | 26.8 (3.5) |
| SA (pmol/mL) — Mean (SD) | 1.45 (1.10) |
| Median (Range) | 1.25 [0-5.70] |

MMSE = Mini-Mental State Examination.

SA = serum anticholinergicity.

Mulsant BH, Pollock BG, et al. Am J Ger Psychiatry. 2002;10(suppl):58.

Logistic Regressions: SA as a Continuous Variable

| | | OR | 95% CI |
|-----------|---------------|-------|----------------|
| Age | | 1.20 | (1.09, 1.32) |
| Sex | Male | 1.00 | |
| 1 | Female | 1.15 | (0.37, 3.57) |
| Education | < high school | 1.00 | |
| | ≥ high school | 0.39 | (0.13,1.21) |
| # of Rx | 0-3 | 1.00 | |
| | ₩ 4-6 | 1.46 | (0.39,5.44) |
| | > 6 | 1.21 | (0.29,5.05) |
| SA | | 16.71 | (2.02, 138.29) |

SA = serum anticholinergicity.

Mulsant BH, Pollock BG, et al. Am J Ger Psychiatry. 2002;10(suppl):58.

Elderly Are More Difficult to Treat Safely

- Pharmacokinetic changes result in higher and more variable drug concentrations
- The elderly often take multiple medications
- Greater sensitivity exists to a given drug concentration
- Homeostatic reserve may be impaired

When To Worry About Drug Interactions

Narrow therapeutic index of victim
Highly potent inducer or inhibitor

Coping With Drug Interactions

Anticipation and prevention
 Highly potent inducer/inhibitor
 Narrow therapeutic index of victim
 Victims dependent on one metabolic enzyme/transport protein

Coping With Drug Interactions

- Recognize interaction potential of "nondrugs" (herbals)
- Keep knowledge base current
- Consider interactions whenever the clinical picture unexpectedly changes

Suggested Readings

DeVane CL, Pollock BG: Pharmacokinetic considerations of antidepressant use in the elderly. J Clin Psychiatry 60[suppl 20]:38-44, 1999.

Lotrich FE, Pollock BG: Aging and clinical pharmacology: Implications for antidepressants. J Clin Pharmacol 45:1106-1122, 2005.

Pollock BG: Treatment of Psychiatric Disorders: General Principles. In: Sadock BJ, Sadock VA, Ruiz P, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Ninth Edition. Philadelphia, PA: Lippincott Williams & Wilkins, pp 4101-4105, 2009.

Chew ML, Mulsant BH, Pollock BG, et al: Anticholinergic Activity of 107 Medications Commonly Used by Older Adults. J Am Geriatrics Soc, 56: 1333-1341, 2008.

- Compared to the rate of ADRs among adults age 20-29, the rate among adults age 80+ is which of the following:
- A. Similar
- B. Twice as great
- C. Greater than 5 x as frequent
- D. Greater than 10 x as frequent

- Commonly prescribed psychiatric medications are substrates of which of the following C450 enzymes?
- A. 1A2
- B. 2D6
- C. 3A4
- D. All of the above

- Which of the following 3A inhibitors can be associated with significant drug/drug interactions when co-administered with a 3A substrate?
- A. Ketoconazole
- B. Erythromycin
- C. Calcium antagonists
- D. Any of the above

- Which of the following medications has anticholinergic properties?
- A. Furosemide
- B. Warfarin
- C. Ranitidine
- D. Digoxin
- E. All the above

- The risk of drug/drug interactions is increased by which of the following?
- A. Narrow therapeutic index of co-administered agent
- B. Highly potent co-administered enzyme inducer or inhibitor
- C. Greater sensitivity to adverse effects in elderly patients
- D. Co-administration of multiple drugs
- E. All the above

Self Assessment Question Answers

◆ 1. C
◆ 2. D
◆ 3. D
◆ 4. E
◆ 5. E